Analysis/NN
of/IN
the/DT
modulation/NN
of/IN
transcriptional/JJ
activity/NN
in/IN
myelopoiesis/NN
and/CC
leukemogenesis/NN
./.

Acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
is/VBZ
still/RB
associated/VBN
with/IN
a/DT
mortality/NN
of/IN
60/CD
to/TO
80/CD
%/NN
./.
=====
AML/NN
is/VBZ
characterized/VBN
by/IN
a/DT
block/NN
in/IN
myeloid/JJ
differentiation/NN
./.
=====
The/DT
transcription/NN
factors/NNS
PU.1/NN
and/CC
C/EBPalpha/NN
are/VBP
responsible/JJ
for/IN
normal/JJ
myeloid/JJ
differentiation/NN
from/IN
stem/NN
cells/NNS
to/TO
monocytes/NNS
or/CC
granulocytes/NNS
./.
=====
In/IN
particular/JJ
,/,
PU.1/NN
induces/VBZ
expression/NN
of/IN
the/DT
macrophage/NN
colony-stimulating/JJ
factor/NN
(/(
M-CSF/NN
)/)
receptor/NN
and/CC
the/DT
development/NN
of/IN
monocytes/NNS
,/,
whereas/IN
C/EBPalpha/NN
increases/VBZ
the/DT
expression/NN
of/IN
the/DT
granulocyte/NN
colony-stimulating/JJ
factor/NN
(/(
G-CSF/NN
)/)
receptor/NN
and/CC
leads/VBZ
to/TO
mature/JJ
granulocytes/NNS
./.
=====
In/IN
AML/NN
,/,
chromosomal/JJ
aberrations/NNS
result/VBP
in/IN
oncoproteins/NNS
such/JJ
as/IN
AML1/ETO/NN
,/,
PML/RARalpha/NN
,/,
or/CC
activated/VBN
Ras/NN
,/,
which/WDT
can/MD
deregulate/VB
genes/NNS
important/JJ
for/IN
normal/JJ
myelopoiesis/NN
./.
=====
Thus/RB
,/,
AML1/ETO/NN
can/MD
bind/VB
to/TO
the/DT
transcription/NN
factor/NN
C/EBPalpha/NN
,/,
inhibit/VB
C/EBPalpha-dependent/JJ
transcription/NN
,/,
and/CC
block/VB
granulocytic/JJ
differentiation/NN
./.
=====
However/RB
,/,
AML1/ETO/NN
can/MD
also/RB
synergize/VB
with/IN
the/DT
transcription/NN
factor/NN
AML1/NN
to/TO
enhance/VB
the/DT
activity/NN
of/IN
the/DT
M-CSF/NN
receptor/NN
promoter/NN
./.
=====
On/IN
the/DT
other/JJ
hand/NN
,/,
the/DT
PML/RARalpha/NN
fusion/NN
protein/NN
causes/VBZ
transcriptional/JJ
repression/NN
by/IN
recruiting/VBG
the/DT
nuclear/JJ
corepressor/NN
(/(
N-CoR/NN
)/)
histone/NN
deacetylase/NN
complex/NN
to/TO
the/DT
DNA/NN
,/,
which/WDT
results/VBZ
in/IN
decreased/VBN
histone/NN
acetylation/NN
and/CC
a/DT
repressive/JJ
chromatin/NN
organization/NN
./.
=====
Here/RB
we/PRP
describe/VBP
methods/NNS
to/TO
investigate/VB
whether/IN
and/CC
how/WRB
signaling/JJ
agonists/NNS
induce/VBP
myeloid/JJ
differentiation/NN
and/CC
how/WRB
oncoproteins/NNS
might/MD
cause/VB
AML/NN
by/IN
modulating/VBG
the/DT
activity/NN
of/IN
transcription/NN
factors/NNS
that/WDT
are/VBP
pivotal/JJ
for/IN
normal/JJ
myeloid/JJ
development/NN
./.
=====
Copyright/NN
1999/CD
Academic/NNP
Press/NNP
./.